<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200725048194N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-04-09</date_registration>
      <primary_sponsor>Rasht University of Medical Sciences</primary_sponsor>
      <public_title>effect of 4% Articaine and 2% Lidocaine infiltration during maxillary primary molar teeth extraction</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of 4% Articaine and 2% Lidocaine infiltration during maxillary primary molar teeth extraction for 6-12 year-old children</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-03-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/62046</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In order to randomize people into two groups A and B, based on the description of the work method, permutation block randomization with block size 6 is used.

Based on the order in which people enter the study, part of the randomization process is given below.
The complete file is available as an Excel file (SAS version 9 software was used for randomization):

Seed: 21650415094698
Block sizes: 6
Actual list length: 54
block identifier, block size, sequence within block, treatment
• 1, 6, 1, Group A
• 1, 6, 2, Group B
• 1, 6, 3, Group A
• 1, 6, 4, Group B
• 1, 6, 5, Group A
• 1, 6, 6, Group B
• 2, 6, 1, Group A
To select the right and left based on the allocation specified in the previous section based on the order specified by considering the left with the letter L and the right with R, the order of selecting the direction will be as follows:

Seed: 21650415094698
Block sizes: 6
Actual list length: 54
block identifier, block size, sequence within block, treatment
• 1, 6, 1, Group R
• 1, 6, 2, Group L
• 1, 6, 3, Group R
• 1, 6, 4, Group L
• 1, 6, 5, Group R
• 1, 6, 6, Group L
• 2, 6, 1, Group R
• 2, 6, 2, Group L
• 2, 6, 3, Group L, Blinding description: Random sequences are placed in opaque sealed envelopes.
Two blinds, an assistant evaluating the outcome, and the patient are unaware of the type of anesthetic. It is not possible for the dentist to blind the material because the injection method is different and the dentist subconsciously notices.</study_design>
      <phase>1-2</phase>
      <hc_freetext>Comparison of the effect of 4% Articaine and 2% Lidocaine infiltration during maxillary primary molar teeth extraction for 6-12 year-old children.</hc_freetext>
      <i_freetext>Intervention 1: Control group: Control group: In the first session for group A patients, injection of 1.8 ml of 4% articaine with epinephrine 1: 1000000 (Daru Pakhsh Company, Tehran, Iran) as buccal infiltration is used and and in the second session, which is at least one week away from the first session, 1.8 ml of 2% lidocaine 2% with epinephrine 1: 80,000 as buccal infiltration is used. Intervention 2: Control group: In the first session for group B patients, injection of 1.8 ml of 2% lidocaine 2% with epinephrine 1: 80,000 (Daru Pakhsh Company, Tehran, Iran) as buccal infiltration is used and and in the second session, which is at least one week away from the first session, 1.8 ml of 4% articaine with epinephrine 1: 1000000 as buccal infiltration is used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Consents and work results for each person

When:
Start access 1 month after printing results

To whom:
Researchers working in academic and scientific institutions

Conditions:
Frequency and percentage are used to describe qualitative data
And for quantitative data, mean and standard deviation will be used
 In addition, suitable descriptive tables and graphs will be used for both measurement scales. Shapiro-Wilk test is used to check the normality of the distribution of the groups and Levene test is used to homogenize the variances. To investigate the relationship and compare groups if the relevant assumptions are made from paired t-test and paired t-test and Generalized estimating equations (GEE) and if the assumptions are not made from Wilcoxon test and in case of no hypotheses for the GEE test, the appropriate conversions proposed by SPSS software (such as square root and logarithm) will be used to establish the hypotheses. . The software used will be spss version 26. Significance level in all tests will be considered 0.05.

Where to obtain:
Maryam Adham Haghighi Pour: maryamad74@gmail.com Dr. Seyedeh Hedye Daneshvar: dr.daneshvar@gums.ac.ir

How to obtain:
Send text to the email mentioned in the previous section using the data.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyedeh Hedyeh Daneshvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Specialized Dental Clinic, after Farhang Square,Imam Street, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1245632145</zip>
        <telephone>+98 13 3332 0060</telephone>
        <email>dr.daneshvar@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyedeh Hedyeh Daneshvar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Specialized Dental Clinic, after Farhang Square,Imam Street, Rasht</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1245632145</zip>
        <telephone>+98 13 3332 0060</telephone>
        <email>dr.daneshvar@gums.ac.ir</email>
        <affiliation>Rasht University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Healthy children 6-12 years old who require primary maxillary molar extraction
The child's cooperation is appropriate for dental treatment under local anesthesia (Class 3 or 4 Frankl scale)
Consent of children's parents to participate in this study</inclusion_criteria>
      <agemin>6 years</agemin>
      <agemax>12 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergic reaction to anesthetic solutions
Having a systemic problem that interferes with the use of epinephrine-containing anesthetics
Receive any medication in the last 24 hours that interferes with the assessment of pain</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Control group: Control group: In the first session for group A patients, injection of 1.8 ml of 4% articaine with epinephrine 1: 1000000 (Daru Pakhsh Company, Tehran, Iran) as buccal infiltration is used and and in the second session, which is at least one week away from the first session, 1.8 ml of 2% lidocaine 2% with epinephrine 1: 80,000 as buccal infiltration is used.</i_keyword>
      <i_keyword>Control group: In the first session for group B patients, injection of 1.8 ml of 2% lidocaine 2% with epinephrine 1: 80,000 (Daru Pakhsh Company, Tehran, Iran) as buccal infiltration is used and and in the second session, which is at least one week away from the first session, 1.8 ml of 4% articaine with epinephrine 1: 1000000 as buccal infiltration is used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Palatal anesthesia by injecting articaine infiltration alone without injecting into the palatal area. Timepoint: after extraction. Method of measurement: Selecting a higher number (1 to 5) of the Smiley Image Scale (FIS) indicates that the child is more dissatisfied.</prim_outcome>
      <prim_outcome>Heart beat. Timepoint: during tooth extraction. Method of measurement: pulse oximeter.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rasht University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-11-24</approval_date>
        <contact_name>ethics committee of Guilan University of Medical sciences</contact_name>
        <contact_address>Namjoo St. - Shahid Siadati St. - Opposite to Shahrivar Hospital - Vice Chancellor for Research and Technology of Guilan University of Medical Sciences Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
